Dementia is an important cause of disability in elderly people. Given the increase in the proportion of elderly people in most countries, the number of patients with dementia will rise and the care of these patients will have a growing impact on the healthcare system and society. The past decade has seen many successes in epidemiological studies of the aetiology of chronic disorders including cardiovascular disease, cancer, and osteoporosis. In this review, new developments in the epidemiology of the dementias are discussed. Descriptive studies of the occurrence of dementia across different populations and time periods as well as studies of risk factors for dementia are reviewed. Dementia is a syndrome that can be caused by many conditions. As Alzheimer's disease is the predominant cause of dementia, accounting for at least half of the cases in most populations, epidemiological research has focused on this disorder.
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*Although based on a medical register, the coverage of this register is such that it may be considered community based.
tIncidence is estimated based on a sample of 642 patients who received detailed clinical examination.
disorders. However, several community based studies have considered the prevalence of dementia-that is, the number of patients with dementia alive in a defined population and time frame. These studies have been reviewed recently.'-3 An important limitation of prevalence studies is that differences in occurrence and survival of disease in a population cannot be distinguished. They are of little value when comparing the risk of dementia across populations. Community based studies of the incidence of dementia-that is, the number of patients that are newly diagnosed in a defined population and time frame-are to be preferred. At present, there are only a limited number of such studies available.' 7 The table shows their general characteristics. In all studies, the diagnosis of dementia and Alzheimer's disease was in accordance with currently accepted criteria. [18] [19] Figures 1 and 2 present age specific incidence rates of dementia and Alzheimer's disease. Up to the age of 75 years, there is little evidence for a large variation in demnentia and Alzheimer's disease between studies. The incidence of Alzheimer's disease seems to be increased in the east Boston study'6; however, this may be explained by the fact that the diagnosis of Alzheimer's disease was based primarily on psychometric testing.4 There is considerable variation in the incidence of dementia and Alzheimer's disease between populations after the age of 75 years, which is not likely to be a result of differences in diagnostic criteria given the lack of variation up to the age of 75 years. However, the few subjects at risk in some studies, methodological problems related to non-response, competing mortality, and comorbidity complicating the diagnosis make it doubtful whether these variations truly reflect a difference in incidence of dementia between populations.
There is some evidence that the relative proportion attributed to the most common subtypes, Alzheimer's disease and vascular dementia, differ between populations.20 In studies of Caucasian populations from Europe and North America, over 50% of all patients with dementia were attributed to Alzheimer's disease compared with only 12-30% to vascular causes. 20 In Asian populations, vascular dementia was found to be underlying the dementia in up to 60% of the patients. 20 In the Epidemiology of the dementias: recent developments and new approaches 24 However, the reduced survival in elderly patients may be a consequence of the reduced life expectancy in the late onset patients. After adjusting for the higher life expectancy in younger patients, a study conducted in New York (the Bronx), suggested that the risk of mortality increased with decreasing age of onset of disease.6 This finding suggests that an earlier onset of disease may be more malignant. Alzheimer's disease is often accompanied by the development of extrapyramidal symptoms, myoclonus, psychosis, seizures, aphasia, and primitive reflexes.'6-'9 Several studies have shown that patients developing one of these symptoms tend to deteriorate to specific cognitive and functional end points more rapidly than those without these symptoms.36-40 It is not clear at present whether these symptoms reflect a clinical subgroup of patients with Alzheimer's disease or whether they are merely markers of disease progression. The finding of an increasing frequency of these symptoms during the course of disease is compatible with the view that these factors are markers of disease progression.'6 On the other hand, the frequency of myoclonus and aphasia early in the course of disease is increased in patients of families in which Alzheimer's disease is linked to a mutation on chromosome 14.4lA3 This suggests that these clinical features reflect different aetiology. The ongoing dissection of Alzheimer's disease by its genetic causes may yield important information on the origin and relevance of concomitant pathology in Alzheimer's disease.
Little is known of the relation between genetic factors and mortality in patients with Alzheimer's disease. The number of patients with dominant mutations is small, which complicates studies on the relation of these mutations to survival. However, it has been shown that patients of families in which Alzheimer's disease is inherited as an autosomal dominant disorder have, in general, a worse progression. 44 Findings on APOE*4 have been controversial. One study reported no association between survival and clinical characteristics,45 whereas other studies suggest that APOE*4 is associated with a slower progression and prolonged survival in patients with Alzheimer's disease. 4 Such studies are prone to various types of bias. Selection bias may have occurred due to mortality in patients related to the risk factor studied. Assessment of exposure to the risk factor has often been based on information from surrogates, which may introduce error. Further, differential misclassification in exposure to risk factors between cases and controls may have occurred, as informants of patients may have been better at recalling exposures than controls. The relation of most risk factors for Alzheimer's disease remains to be confirmed in follow up studies of incident patients, in which the exposure state is measured before the onset of disease.
AGE AND SEX
The risk of dementia and Alzheimer's disease increases strongly with age (see figs 1 and 2),'-' suggesting that genetic and environmental factors which influence aging of the brain may play an important part. Two studies of the incidence of Alzheimer's disease found that the disease occurred more often in women than men,5 '7 but most studies show a similar incidence in men and women.489 14 Vascular dementia has been found to be more frequent in men than women,414'7 which probably reflects the higher frequency of vascular disease in men. The incidence of vascular dementia in men and women increased with age in the long term follow up study conducted in Lundby.5 By contrast, an increase in incidence of vascular dementia with age was found only in women in the study conducted in the Bordeaux area in France.'4 However, the number of patients studied was small.
GENETIC RISK FACTORS
Alzheimer's disease aggregates within families of patients with early and late onset of disease. 54 Several genes (APP, PS-1, PS-2) have been identified that are involved in the autosomal dominant forms of early onset Alzheimer's disease.26-29 However, the role of these genes in late onset Alzheimer's disease, which concerns the vast majority of patients in the population, is limited. In the patients with late onset disease, the APOE gene on chromosome 19 seems to play a part.'0-2 Other forms of dementia including vascular dementia,6' 62
Lewy body disease,6' and Creutzfeldt-Jakob disease64 have also been associated with APOE*4. Further, APOE*4 has been associated with decreased cognitive function and increased rates of cognitive decline in the general population. [65] [66] [67] [68] Despite the fact that many studies have consistently shown an increased risk of Alzheimer's disease for APOE*4 carriers,69 some questions remain to be clarified to identify clinically relevant risk groups. There is still controversy about whether the risk associated with the APOE*4 allele may be modified by sex, [70] [71] [72] 48 The discrepancies may also be a result of the reduced survival of patients with APOE*2.48 As most studies were based on prevalent cases, APOE*2 carriers may have been selectively removed from the patient series over time. This may have resulted in an apparent decrease of the APOE*2 allele frequency. In a similar way, the increased survival for patients with Alzheimer's disease with APOE*4 that has been found in some studies may have led to an overrepresentation of APOE*4 carriers in patients with Alzheimer's disease.4F48
Although it is unlikely that the relation between APOE*4 and Alzheimer's disease can be explained fully by survival effects, reduced mortality in APOE*4 carriers may have led to an overestimation of the risk of Alzheimer's disease associated with the APOE*4 allele. 48 The mechanism through which APOE affects the risk of Alzheimer's disease and other types of dementia remains to be elucidated. The APOE*4 allele has been implicated in various aspects of Alzheimer's disease pathology including ,6 A4 amyloid deposition in senile plaques as well as in microtubule instability and paired helical filament formation.30 81 89 However, the negative findings may be a result of the low statistical power of individual studies.
As the frequency of Alzheimer's disease in the population is considerably higher than the frequency of Down's syndrome, studies of family history of dementia in patients with Down's syndrome have a higher statistical power. Although the early studies on family history did not yield consistent results,909' a recent study has shed new light on this issue.92
The study showed an increased risk of dementia in mothers of patients with Down's syndrome, but not in fathers, suggesting that non-dysjunction of chromosomes in the mother may play a part in familial aggregation of Down's syndrome and Alzheimer's disease. 92 The risk of dementia in mothers was increased only when the mother was younger than 35 89 but another reported a non-significant increase in risk of Alzheimer's disease in subjects with a history of depression in the previous three years. 86 Familial aggregation of depression has been reported in patients with Alzheimer's disease and a positive family history of dementia.'02 This suggests that genetic factors may underlie the relation.'02 However, it remains to be excluded that depression is merely an early sign of Alzheimer pathology.
THYROID DISEASE
There is some evidence from the early studies of risk factors for Alzheimer's disease for an increased risk of disease in patients with hypothyroidism.57 Further, an association between Alzheimer's disease and autoimmune thyroid disease has been reported in Down's syndrome and familial Alzheimer's disease.'03 104 None of the recent studies has confirmed the association with thyroid disease.838889 However, these studies were based on data from informants. One study on the history of thyroid disease based on medical records suggested that the risk of Alzheimer's disease was decreased for patients with Graves' disease, whereas there was a nonsignificant increase in risk for patients with myxoedema.105 These findings and their pathophysiological importance remain to be clarified.
VASCULAR FACTORS
In recent years, the interest in vascular causes of dementia has increased, partly because there may be opportunities for prevention and treatment for this type of dementia. By definition, vascular disease and its risk factors must be present in patients with vascular dementia. 25 Factors that have been implicated in the risk of vascular dementia include hypertension, diabetes mellitus, and cardiovascular disease.'06 The mechanism through which these factors lead to dementia is unclear. Vascular factors may also be involved in Alzheimer's disease.'06 However, their role is difficult to quantify as patients with vascular disease are less likely to be diagnosed as cases of Alzheimer's disease. '8 19 White matter lesions have been found in increased frequency in patients with Alzheimer's disease in some studies but not in others.'07 108 Although these lesions have been associated with atherosclerosis,109 they are not specific and may reflect cerebral atrophy and amyloid angiopathy in patients with Alzheimer's disease.'07 108 There is evidence from one MRI study that suggests that arteriolosclerosis may be specific for patients with late onset Alzheimer's disease.'08
ANTI-INFLAMMATORY DRUGS
From experimental studies, there is increasing evidence that acute and chronic inflammatory processes play an important part in the pathophysiology of Alzheimer's disease." 10 11' Novel findings that may have clinical relevance are the inverse relations between Alzheimer's disease and past use of anti-inflammatory drugs and with rheumatoid arthritis, a disorder for which these drugs are often prescribed. 8489 112, 14 As the only follow up study failed to show a relation between rheumatoid arthritis and Alzheimer's disease," 5 a possible protective effect of anti-inflammatory drugs remains to be clarified. Preliminary evidence showing that cognitive decline may be less in subjects taking indomethacin than in control subjects, indicates that further studies may be of interest.116 OESTROGEN REPLACEMENT THERAPY Oestrogen may be implicated in Alzheimer's disease in several ways. Improvement of cerebral blood flow, direct stimulation of neurons, development of gliacytes, and suppression of apolipoprotein E have been suggested."17 However, findings of epidemiological studies have been controversial. One study, based on computerised pharmaceutical records, did not show evidence for a relation,"18 whereas two studies based on anamnestic data suggested a protective effect of oestrogen replacement therapy."9 120 There are important methodological problems which make the interpretation of the latter studies difficult. In one, a follow up study, based on direct interviews before onset of disease, the diagnosis of Alzheimer's disease at follow up depended on mortality records."9 Mortality records have been shown to be unreliable for the ascertainment of patients with Alzheimer's disease. In the other study, the history of oestrogen use was obtained from informants for cases of Alzheimer's disease but from the control women directly. '20 Lack of knowledge of the use of oestrogens by the informant may explain part of the inverse relation found. Although some experimental studies on oestrogen suggest a beneficial effect,'17 there is no convincing evidence from epidemiological studies confirming such a role of oestrogen in Alzheimer's disease.
SMOKING HISTORY
Early epidemiological studies suggested an inverse association between Alzheimer's disease and history of smoking,59 but recent studies have yielded equivocal results. The association between smoking and Alzheimer's disease was found to be absent in three studies,88 89 121 inverse in two,122 123 and positive in one. 86 The inverse association seemed to be related to social class in one study. 123 The results of a recent meta-analysis were compatible with a decreased risk of Alzheimer's disease in smokers. 124 There is some evidence that genetic factors, including the APOE gene, may alter the association between smoking and Alzheimer's disease. 93 125 The inverse relation between smoking and Alzheimer's disease was found to be limited to those with the APOE*4 allele that had a positive family history.93 125 However, modification of the relation between smoking and Alzheimer's disease by APOE has not been confirmed in other studies. 126 Experimental studies of rats and rabbits have suggested that nicotine may improve memory and cognition.127 Moreover, blockade of nicotinic receptor function may produce a significant cognitive impairment in humans'28 and clinical trials have suggested that nicotine and nicotine derivatives may improve information processing and attention in patients with Alzheimer's disease.129 130 However, there was no evidence for improvements in memory or cognition. '29 130 This suggests that nicotine or its derivates modifies a rather limited spectrum of the clinical course of the disease.
Most studies of Parkinson's disease have also reported an inverse association with smoking.'3' By contrast with the findings on Alzheimer's disease and Parkinson's disease, the risk of vascular dementia was found to be increased for subjects that smoked,'06 suggesting a different effect of smoking in these disorders, rather than a general mechanism between smoking and dementia.
ALCOHOL
There was no evidence for an increase in risk of Alzheimer's disease in people with a moderate alcohol intake in a reanalysis of early casecontrol studies of Alzheimer's disease. 59 However, more recent studies of the association between aluminum and the Alzheimer pathology have yielded contradicting results. '35 On the other hand, there is growing evidence from experimental studies that aluminum may influence the conformation of both amyloid and neurofibrillary tangles. '36'138 Follow up studies of the presence of Alzheimer pathology in the brains of patients who were on dialysis and exposed to high doses of aluminum have not been conclusive. '39 140 Epidemiological studies on the association between aluminum in drinking water and the risk of Alzheimer's disease have been reviewed recently. 141 With the exception of one study,88 findings have been consistent in suggesting an increased risk of Alzheimer's disease with increasing aluminum concentration in drinking water.'4' 142 However, the possibility of bias in present studies still outweighs the evidence for causal inference.14' Studies that have considered the role of aluminum products such as antacids and antiperspirants have yielded equivocal results.8489 Supporting a role of aluminum in Alzheimer's disease was the finding of a lower level of cognitive functioning among miners treated with aluminum powder'43 and the finding of a slower progression of the disease in patients with Alzheimer's disease treated with aluminum chelating drugs. 144 Despite the strong evidence from experimental studies that aluminum may be implicated in the Alzheimer pathology and progression of the disease, there are many questions to be answered from an epidemiological point of view. An issue that complicates the interpretation of the negative studies is the possibility that the effect of aluminum may depend on an interaction with other environmental factors. For instance, the risk of Alzheimer's disease associated with aluminum in drinking water may be influenced by the pH142 or the presence of silicon. increase in the risk of Alzheimer's disease. Familial aggregation of Alzheimer's disease with Down's syndrome, depression, and perhaps Parkinson's disease suggests that there may be a common genetic factor underlying these disorders in at least a subgroup of patients. As to environmental factors, the influence of alcohol and smoking is still controversial. Given the widespread exposure to aluminum through food products and drinking water, the relation between aluminum and Alzheimer's disease deserves further attention.
Epidemiological research on Alzheimer's disease is far from its limits. Most studies of risk factors for this disease have been small, whereas risk factors were rare. 53 The validity of studies has been compromised by anamnestic data collected through surrogate informants. Long term follow up studies, that are currently ongoing, will overcome these problems. Nonresponse, competing mortality, and comorbidity complicating the diagnosis, in particular in elderly people, will be challenges to overcome in these studies. However, advances in epidemiological research will not depend only on improved methodology. Recent epidemiological studies have led to preliminary findings of a protective effect of anti-inflammatory drugs and perhaps oestrogen replacement therapy that may prove to be of clinical relevance. Progress in the understanding of the genetics of Alzheimer's disease and other types of dementia has opened new possibilities for epidemiological studies on the risk associated with these genetic factors. Firstly, the risk of Alzheimer's disease associated with the various genetic factors identified including APOE remains to be quantified in follow up studies of incident cases. Secondly, the possibility of interaction between genetic and environmental risk factors needs to be studied, as the strength of association between an environmental factor and the risk of disease may depend on the presence of a genetic factor."3 Conversely, the effect of the genetic factor on the risk of Alzheimer's disease may be conditional on the presence of other genetic and environmental risk factors.93 For APOE, there is some evidence for synergistic effects of APOE*4, head trauma, and cholesterol and antagonistic effects of APOE*4 and smoking with regard to the risk of Alzheimer's disease.72 100 125 Interaction of APOE with other possible risk factors including vascular factors needs to be studied further. As pathological and molecular biological research proceeds, Alzheimer's disease and other types of dementia are likely to be dissected further into aetiologically relevant subgroups.
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